Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Azacytidine and Nivolumab in Resectable HPV-Associated Head and Neck Squamous Cell Cancer
NCT05317000Phase 2Recruiting
- Start
- Mar 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of azacitidine in head and neck squamous cell carcinoma (HNSCC) (2 arms). Primary endpoint: Immune-related pathologic response. Started Mar 2023; status: recruiting.
02
Drugs
azacitidine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05317000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317000.